Transition Therapeutics (TTHI) Doses First Patient in TT-401 Phase 1
Transition Therapeutics Inc. (Nasdaq: TTHI) reports that the first patient has been dosed in a Phase 1 clinical study of type 2 diabetes drug candidate, TT-401. TT-401 is a once-weekly administered peptide being studied for its potential to lower blood glucose levels in patients with type 2 diabetes and accompanying obesity.
Currently approved GLP-1 agonist therapies are a fast growing therapeutic segment emerging as an important approach in the treatment of type 2 diabetes. Next generation therapies for type 2 diabetes are currently being studied in early clinical development for their potential to provide a superior product profile over current GLP-1 product offerings through improved efficacy, broader therapeutic application or less frequent administration. Preclinical data on TT-401 show potential for TT-401 to be administered once-weekly and provide sustained glycemic control and other beneficial effects including weight loss and improvements in lipid profile.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Currently approved GLP-1 agonist therapies are a fast growing therapeutic segment emerging as an important approach in the treatment of type 2 diabetes. Next generation therapies for type 2 diabetes are currently being studied in early clinical development for their potential to provide a superior product profile over current GLP-1 product offerings through improved efficacy, broader therapeutic application or less frequent administration. Preclinical data on TT-401 show potential for TT-401 to be administered once-weekly and provide sustained glycemic control and other beneficial effects including weight loss and improvements in lipid profile.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Auxilium (AUXL) Files Suit Against Watson (WPI) Over Testim 1% Gel
- Vertex Pharmaceuticals (VRTX) Gets Positive Opinion from CHMP for KALYDECO
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
